BioCentury | Feb 25, 2021
Finance

Foresite raises nearly $1B to back data science plays with fifth fund, incubator

With $969 million raised across two new funds, Foresite Capital plans to continue putting its money to work in data-driven healthcare companies. Foresite Capital Fund V and Foresite Capital Opportunity Fund V will invest in...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH) in a cash and stock transaction valued at about $12 billion. The deal combines ICON’s Accellacare site network, home health services and wearables expertise...
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...
BioCentury | Feb 23, 2021
Deals

Beam adds ex-hepatic delivery tech to base editing toolkit with Guide buyout

Beam will take advantage of a months-long run-up in its share price to add a key base editing delivery technology via its takeout of privately held Guide Therapeutics, providing an early exit for investors less...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead...
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The candidate is under FDA and EMA review.  Sanofi is...
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

President Biden nominated Chiquita Brooks-LaSure as CMS administrator. Brooks-LaSure previously served under the Obama administration as deputy director for policy at CMS’ Center for Consumer Information and Insurance Oversight and as director of coverage policy at...
BioCentury | Feb 19, 2021
Product Development

First-time CEOs must stop doing what made them successful: Guest Commentary

First-time CEOs of biotechs must not fall in the trap of continuing to excel in the domain areas their career success has been built on. Effectively stepping up to the chief executive role requires getting...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes. Primmune Therapeutics Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream receptor for...
Items per page:
1 - 10 of 13758
BioCentury | Feb 25, 2021
Finance

Foresite raises nearly $1B to back data science plays with fifth fund, incubator

With $969 million raised across two new funds, Foresite Capital plans to continue putting its money to work in data-driven healthcare companies. Foresite Capital Fund V and Foresite Capital Opportunity Fund V will invest in...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

After its $135 million series C raise Wednesday, Vividion has everything in place to take advantage of the surging market for IPOs: a broad syndicate of crossover investors, pharma partners in BMS and Roche, a CEO...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

ICON plc (NASDAQ:ICLR) is buying fellow CRO PRA Health Sciences Inc. (NASDAQ:PRAH) in a cash and stock transaction valued at about $12 billion. The deal combines ICON’s Accellacare site network, home health services and wearables expertise...
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...
BioCentury | Feb 23, 2021
Deals

Beam adds ex-hepatic delivery tech to base editing toolkit with Guide buyout

Beam will take advantage of a months-long run-up in its share price to add a key base editing delivery technology via its takeout of privately held Guide Therapeutics, providing an early exit for investors less...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead...
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The candidate is under FDA and EMA review.  Sanofi is...
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

President Biden nominated Chiquita Brooks-LaSure as CMS administrator. Brooks-LaSure previously served under the Obama administration as deputy director for policy at CMS’ Center for Consumer Information and Insurance Oversight and as director of coverage policy at...
BioCentury | Feb 19, 2021
Product Development

First-time CEOs must stop doing what made them successful: Guest Commentary

First-time CEOs of biotechs must not fall in the trap of continuing to excel in the domain areas their career success has been built on. Effectively stepping up to the chief executive role requires getting...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes. Primmune Therapeutics Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream receptor for...
Items per page:
1 - 10 of 13758